Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C10H16N2O3S |
| Molecular Weight | 244.311 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)CCCC[C@@H]1SC[C@@H]2NC(=O)N[C@H]12
InChI
InChIKey=YBJHBAHKTGYVGT-ZKWXMUAHSA-N
InChI=1S/C10H16N2O3S/c13-8(14)4-2-1-3-7-9-6(5-16-7)11-10(15)12-9/h6-7,9H,1-5H2,(H,13,14)(H2,11,12,15)/t6-,7-,9-/m0/s1
| Molecular Formula | C10H16N2O3S |
| Molecular Weight | 244.311 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
DescriptionSources: www.ncbi.nlm.nih.gov/pubmed/18356320Curator's Comment: description was created based on several sources, including
www.ncbi.nlm.nih.gov/pubmed/17182796,
www.ncbi.nlm.nih.gov/pubmed/19056639
Sources: www.ncbi.nlm.nih.gov/pubmed/18356320
Curator's Comment: description was created based on several sources, including
www.ncbi.nlm.nih.gov/pubmed/17182796,
www.ncbi.nlm.nih.gov/pubmed/19056639
Biotin (also known as vitamin H and vitamin B7) is a water-soluble vitamin which is required for normal cellular functions, growth and development. Biotin is an important cofactor for many mitochondria and cytoplasm enzymes: acetyl-CoA carboxylase a (ACCa),7 ACCb, pyruvate carboxylase (PC), propionyl-CoA carboxylase (PCC), and methylcrotonyl-CoA carboxylase (MCC) and plays critical role in in the intermediate metabolism of gluconeogenesis, fatty acid synthesis, and amino acid catabolism. The vitamin cannot be synthesized by humans and must be obtained from diet. If there is a lack of biotin, an organism starts suffering from biotin deficiency, a condition which is very common among pregnant women, for example. The vitamin deficiency effects hair, nail growth and skin health. For preventing measures, biotin should be taken as a dietary supplement (in a form of vitamin complex or as a pure biotin) which are marketed worldwide under different names. Biotin is a part of many formulations which were approved by FDA.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/3098919
Curator's Comment: Biotin was shown to cross the blood brain barrier in rats.
Approval Year
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Preventing | INFUVITE ADULT Approved UseINFUVITE ADULT is a combination of vitamins indicated for prevention of vitamin deficiency in adults and children aged 11 and older receiving parenteral nutrition. Launch Date2000 |
|||
| Preventing | BIOTIN Approved UseAs a dietary supplement. |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
494.9 ng/mL |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
BIOTIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
823.8 ng/mL |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
BIOTIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
41 ng/mL |
5 mg 1 times / day steady-state, oral dose: 5 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
BIOTIN serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
91 ng/mL |
10 mg 1 times / day steady-state, oral dose: 10 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
BIOTIN serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
184 ng/mL |
20 mg 1 times / day steady-state, oral dose: 20 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
BIOTIN serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
84.8 ng/mL |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
BIOTIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
|
214.6 ng/mL |
40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered: |
BIOTIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
|
508.5 ng/mL |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
BIOTIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
2315 ng × h/mL |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
BIOTIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
4010 ng × h/mL |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
BIOTIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
210 ng × h/mL |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
BIOTIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
|
605.1 ng × h/mL |
40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered: |
BIOTIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
|
1652.4 ng × h/mL |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
BIOTIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
15 h |
5 mg 1 times / day steady-state, oral dose: 5 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
BIOTIN serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
15 h |
10 mg 1 times / day steady-state, oral dose: 10 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
BIOTIN serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
15 h |
20 mg 1 times / day steady-state, oral dose: 20 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
BIOTIN serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
Funbound
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
81% |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
BIOTIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
81% |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
BIOTIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Erbin is a protein concentrated at postsynaptic membranes that interacts with PSD-95. | 2001-06-01 |
|
| Functional signal peptides bind a soluble N-terminal fragment of SecA and inhibit its ATPase activity. | 2001-06-01 |
|
| Structural characterization of pyrrolic cross-links in collagen using a biotinylated Ehrlich's reagent. | 2001-06-01 |
|
| Adsorption of avidin on microfabricated surfaces for protein biochip applications. | 2001-05-20 |
|
| Rotation of a complex of the gamma subunit and c ring of Escherichia coli ATP synthase. The rotor and stator are interchangeable. | 2001-05-04 |
|
| Immobilization of sugar-non-specific nucleases by utilizing the streptavidin--biotin interaction. | 2001-05-04 |
|
| Sodium ion-translocating decarboxylases. | 2001-05-01 |
|
| Coupling mechanism of the oxaloacetate decarboxylase Na(+) pump. | 2001-05-01 |
|
| Mu-opioid receptors are present in functionally identified sympathoexcitatory neurons in the rat rostral ventrolateral medulla. | 2001-04-23 |
|
| Progress towards single-molecule sequencing: enzymatic synthesis of nucleotide-specifically labeled DNA. | 2001-04-13 |
|
| Polymer support for exonucleolytic sequencing. | 2001-04-13 |
|
| A new quantitative analytical method of serum biotinidase activity using biocytin as a substrate and its clinical significance in Japan. | 2001-04 |
|
| Avidin expression during chick chondrocyte and myoblast development in vitro and in vivo: regulation of cell proliferation. | 2001-04 |
|
| Neurotrophic actions of novel compounds designed from cyclopentenone prostaglandins. | 2001-04 |
|
| Optical measurement of transverse molecular diffusion in a microchannel. | 2001-04 |
|
| Propagation of synchronous epileptiform events from subiculum backward into area CA1 of rat brain slices. | 2001-03-23 |
|
| [New stage in the immunogram technique--visual streptavidin-biotin method]. | 2001-03-15 |
|
| Metabolic biotinylation of secreted and cell surface proteins from mammalian cells. | 2001-03-09 |
|
| Cloning and characterization of biotin biosynthetic genes of Kurthia sp. | 2001-03-07 |
|
| Association of membrane-bound amyloid precursor protein APP with the apolipoprotein E receptor LRP. | 2001-03-05 |
|
| Investigating the surface expression of the renal type IIa Na+/Pi-cotransporter in Xenopus laevis oocytes. | 2001-03-01 |
|
| Axonal transport of TNF-alpha in painful neuropathy: distribution of ligand tracer and TNF receptors. | 2001-03-01 |
|
| Single epitope multiple staining to detect ultralow frequency B cells. | 2001-03-01 |
|
| Abnormal thiol reactivity of tropomyosin in essential hypertension and its association with abnormal sodium-lithium countertransport kinetics. | 2001-03 |
|
| Neuroendocrine differentiation in bronchial carcinomas of classic squamous-cell type: an immunohistochemical study of 29 cases applying the tyramide signal amplification technique. | 2001-03 |
|
| In situ hybridization detection of calcitonin mRNA in routinely fixed, paraffin-embedded tissue sections: a comparison of different types of probes combined with tyramide signal amplification. | 2001-03 |
|
| Stimulation of corticospinal tract regeneration in the chronically injured spinal cord. | 2001-03 |
|
| PCR-ELISAs for the detection of Campylobacter jejuni and Campylobacter coli in poultry samples. | 2001-03 |
|
| Synthesis and application of circularizable ligation probes. | 2001-03 |
|
| Screening effect of PEG on avidin binding to liposome surface receptors. | 2001-02-19 |
|
| Relationship between serum biotin concentration and moisture content of the sole horn in cows with clinical laminitis or sound hooves. | 2001-02-17 |
|
| Stimulation of intercellular communication of poor-communicating cells by gap-junction-competent cells enhances the HSV-TK/GCV bystander effect in vitro. | 2001-02-15 |
|
| Longitudinal study of anti-Candida albicans mucosal immunity against aspartic proteinases in HIV-infected patients. | 2001-02-01 |
|
| In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B. | 2001-02-01 |
|
| The Bacillus subtilis RNase P holoenzyme contains two RNase P RNA and two RNase P protein subunits. | 2001-02 |
|
| Effects of supplemental dietary biotin on performance of Holstein cows during early lactation. | 2001-02 |
|
| Reconstruction of the transected cat spinal cord following NeuroGel implantation: axonal tracing, immunohistochemical and ultrastructural studies. | 2001-02 |
|
| Axon trajectories in local circuits of the primary motor cortex in the macaque monkey (Macaca fuscata). | 2001-02 |
|
| An in situ hybridization protocol to detect rare mRNA expressed in neural tissue using biotin-labelled oligonucleotide probes. | 2001-02 |
|
| Expression sequence tag-specific full-length cDNA cloning: actin cDNAs. | 2001-01-24 |
|
| Origin and propagation of spontaneous excitation in smooth muscle of the guinea-pig urinary bladder. | 2001-01-15 |
|
| Avidin-biotin-immobilized liposome column for chromatographic fluorescence on-line analysis of solute-membrane interactions. | 2001-01-05 |
|
| Combined laser tweezers and dielectric field cage for the analysis of receptor-ligand interactions on single cells. | 2001-01 |
|
| Azospirillum doebereinerae sp. nov., a nitrogen-fixing bacterium associated with the C4-grass Miscanthus. | 2001-01 |
|
| Postnatal development of biotinylated dextran amine-labeled corpus callosum axons projecting from the visual and auditory cortices to the visual cortex of the rat. | 2001-01 |
|
| Thalamocortical arbors extend beyond single cortical barrels: an in vivo intracellular tracing study in rat. | 2001-01 |
|
| Enhanced surface plasmon resonance immunosensing using a streptavidin-biotinylated protein complex. | 2001-01 |
|
| [Development and identification of T. aestivum-S. cereale-H. villosa double translocation line 1RS.1BL, 6VS.6AL via chromosome C-banding and dual color FISH]. | 2001 |
|
| Intra- and inter-areal connections between the primary visual cortex V1 and the area immediately surrounding V1 in the rat. | 2001 |
|
| Immunohistochemistry of MMPs and TIMPs. | 2001 |
Patents
Sample Use Guides
In Vivo Use Guide
Curator's Comment: https://cscprivatelabel.com/wp-content/uploads/2016/05/Biotin.pdf
Recommended daily dosage is 10 ml (in a form of infuvite adult) or 1 tablet a day in a form of Biotin dietary supplement (the dosage may vary).
Route of Administration:
Other
Human T lymphoma Jurkat cells and monocytic myeloid U937 cells were incubated with different concentrations of biotin (nM): 0.025, 0.25 and 10, representing plasma levels in biotin-deficient, biotin-sufficient and biotin-supplemented adults. When taken together with folate, biotin synergizes in the repression of pro-inflammatory cytokines and long-terminal repeats (LTRs), mediated by interactions between HLCS and other chromatin proteins.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:54:24 GMT 2025
by
admin
on
Mon Mar 31 17:54:24 GMT 2025
|
| Record UNII |
6SO6U10H04
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
DSLD |
2669 (Number of products:7171)
Created by
admin on Mon Mar 31 17:54:24 GMT 2025 , Edited by admin on Mon Mar 31 17:54:24 GMT 2025
|
||
|
WHO-VATC |
QA11HA05
Created by
admin on Mon Mar 31 17:54:24 GMT 2025 , Edited by admin on Mon Mar 31 17:54:24 GMT 2025
|
||
|
FDA ORPHAN DRUG |
760720
Created by
admin on Mon Mar 31 17:54:24 GMT 2025 , Edited by admin on Mon Mar 31 17:54:24 GMT 2025
|
||
|
LOINC |
34398-8
Created by
admin on Mon Mar 31 17:54:24 GMT 2025 , Edited by admin on Mon Mar 31 17:54:24 GMT 2025
|
||
|
LIVERTOX |
NBK548710
Created by
admin on Mon Mar 31 17:54:24 GMT 2025 , Edited by admin on Mon Mar 31 17:54:24 GMT 2025
|
||
|
LOINC |
31997-0
Created by
admin on Mon Mar 31 17:54:24 GMT 2025 , Edited by admin on Mon Mar 31 17:54:24 GMT 2025
|
||
|
DSLD |
22 (Number of products:127)
Created by
admin on Mon Mar 31 17:54:24 GMT 2025 , Edited by admin on Mon Mar 31 17:54:24 GMT 2025
|
||
|
WHO-ATC |
A11HA05
Created by
admin on Mon Mar 31 17:54:24 GMT 2025 , Edited by admin on Mon Mar 31 17:54:24 GMT 2025
|
||
|
NCI_THESAURUS |
C45812
Created by
admin on Mon Mar 31 17:54:24 GMT 2025 , Edited by admin on Mon Mar 31 17:54:24 GMT 2025
|
||
|
LOINC |
1980-2
Created by
admin on Mon Mar 31 17:54:24 GMT 2025 , Edited by admin on Mon Mar 31 17:54:24 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
6SO6U10H04
Created by
admin on Mon Mar 31 17:54:24 GMT 2025 , Edited by admin on Mon Mar 31 17:54:24 GMT 2025
|
PRIMARY | |||
|
SUB32335
Created by
admin on Mon Mar 31 17:54:24 GMT 2025 , Edited by admin on Mon Mar 31 17:54:24 GMT 2025
|
PRIMARY | |||
|
15956
Created by
admin on Mon Mar 31 17:54:24 GMT 2025 , Edited by admin on Mon Mar 31 17:54:24 GMT 2025
|
PRIMARY | |||
|
63865
Created by
admin on Mon Mar 31 17:54:24 GMT 2025 , Edited by admin on Mon Mar 31 17:54:24 GMT 2025
|
PRIMARY | |||
|
346
Created by
admin on Mon Mar 31 17:54:24 GMT 2025 , Edited by admin on Mon Mar 31 17:54:24 GMT 2025
|
PRIMARY | |||
|
373
Created by
admin on Mon Mar 31 17:54:24 GMT 2025 , Edited by admin on Mon Mar 31 17:54:24 GMT 2025
|
PRIMARY | |||
|
200-399-3
Created by
admin on Mon Mar 31 17:54:24 GMT 2025 , Edited by admin on Mon Mar 31 17:54:24 GMT 2025
|
PRIMARY | |||
|
DTXSID7022679
Created by
admin on Mon Mar 31 17:54:24 GMT 2025 , Edited by admin on Mon Mar 31 17:54:24 GMT 2025
|
PRIMARY | |||
|
6SO6U10H04
Created by
admin on Mon Mar 31 17:54:24 GMT 2025 , Edited by admin on Mon Mar 31 17:54:24 GMT 2025
|
PRIMARY | |||
|
58-85-5
Created by
admin on Mon Mar 31 17:54:24 GMT 2025 , Edited by admin on Mon Mar 31 17:54:24 GMT 2025
|
PRIMARY | |||
|
1071508
Created by
admin on Mon Mar 31 17:54:24 GMT 2025 , Edited by admin on Mon Mar 31 17:54:24 GMT 2025
|
PRIMARY | |||
|
1203
Created by
admin on Mon Mar 31 17:54:24 GMT 2025 , Edited by admin on Mon Mar 31 17:54:24 GMT 2025
|
PRIMARY | |||
|
CHEMBL857
Created by
admin on Mon Mar 31 17:54:24 GMT 2025 , Edited by admin on Mon Mar 31 17:54:24 GMT 2025
|
PRIMARY | |||
|
m2506
Created by
admin on Mon Mar 31 17:54:24 GMT 2025 , Edited by admin on Mon Mar 31 17:54:24 GMT 2025
|
PRIMARY | Merck Index | ||
|
BIOTIN
Created by
admin on Mon Mar 31 17:54:24 GMT 2025 , Edited by admin on Mon Mar 31 17:54:24 GMT 2025
|
PRIMARY | |||
|
1588
Created by
admin on Mon Mar 31 17:54:24 GMT 2025 , Edited by admin on Mon Mar 31 17:54:24 GMT 2025
|
PRIMARY | |||
|
SUB05841MIG
Created by
admin on Mon Mar 31 17:54:24 GMT 2025 , Edited by admin on Mon Mar 31 17:54:24 GMT 2025
|
PRIMARY | |||
|
171548
Created by
admin on Mon Mar 31 17:54:24 GMT 2025 , Edited by admin on Mon Mar 31 17:54:24 GMT 2025
|
PRIMARY | |||
|
100000092789
Created by
admin on Mon Mar 31 17:54:24 GMT 2025 , Edited by admin on Mon Mar 31 17:54:24 GMT 2025
|
PRIMARY | |||
|
D001710
Created by
admin on Mon Mar 31 17:54:24 GMT 2025 , Edited by admin on Mon Mar 31 17:54:24 GMT 2025
|
PRIMARY | |||
|
C309
Created by
admin on Mon Mar 31 17:54:24 GMT 2025 , Edited by admin on Mon Mar 31 17:54:24 GMT 2025
|
PRIMARY | |||
|
DB00121
Created by
admin on Mon Mar 31 17:54:24 GMT 2025 , Edited by admin on Mon Mar 31 17:54:24 GMT 2025
|
PRIMARY | |||
|
57586
Created by
admin on Mon Mar 31 17:54:24 GMT 2025 , Edited by admin on Mon Mar 31 17:54:24 GMT 2025
|
PRIMARY | |||
|
314583
Created by
admin on Mon Mar 31 17:54:24 GMT 2025 , Edited by admin on Mon Mar 31 17:54:24 GMT 2025
|
ALTERNATIVE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|